Pfizer Q4 Earnings Eke Out Unexpected Profit Despite Lower COVID Product SalesInvestopedia • 01/30/24
Pfizer Reports Surprise Profit Despite Continued Covid Sales DownfallInvestors Business Daily • 01/30/24
Pfizer's stock rises as earnings beat expectations, company seeks ‘clean slate' in 2024Market Watch • 01/30/24
Is there a doctor in the house? Pfizer reports critically low income and revenues in financial resultsInvezz • 01/30/24
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial GuidanceBusiness Wire • 01/30/24
2 Ultra-High-Yield Dividend Stocks Down 47% or More to Buy Hand Over Fist Right NowThe Motley Fool • 01/27/24
European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder CancerBusiness Wire • 01/26/24
European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder CancerPRNewsWire • 01/26/24